Doximity
DOCS
$20.45
+0.74%
Doximity, Inc. operates a digital platform exclusively for U.S. medical professionals, providing tools for collaboration, secure patient care coordination, virtual visits, medical news, and career management within the Healthcare Information Services industry. The company is the dominant network and platform for physicians in the U.S., establishing itself as a critical, high-margin infrastructure player in the healthcare ecosystem. The current investor narrative is dominated by a sharp stock price decline following a disappointing earnings report in May 2026, which revealed a significant slowdown in future revenue growth, forcing a debate between its strong, profitable market position and the near-term headwinds impacting its growth trajectory.…
DOCS
Doximity
$20.45
Related headlines
Investment Opinion: Should I buy DOCS Today?
Rating: Hold. The core thesis is that Doximity is a high-quality business experiencing a severe but potentially temporary growth scare, making it a speculative turnaround candidate rather than a clear buy at this juncture.
Supporting this view are several specific data points: 1) The valuation has compressed dramatically to a forward P/E of 13.4x, suggesting much of the bad news is priced in. 2) Underlying profitability remains exceptional, with gross margins of 89.9% and robust free cash flow generation of $311.5M TTM. 3) The balance sheet is fortress-like with minimal debt (D/E of 0.011). 4) The stock is deeply oversold, trading just 28% above its 52-week low, which may limit near-term downside.
The two biggest risks are persistent growth deceleration below 10% and a breakdown below the $17.15 support level. This Hold rating would upgrade to a Buy if the company demonstrates a clear re-acceleration of revenue growth back above 15% YoY or if the forward P/E compresses further into the single digits on sustained profitability. It would downgrade to a Sell if revenue growth decelerates into the mid-single digits or net margins contract below 25%. Relative to its own history of premium multiples, the stock appears fairly to slightly undervalued, but this discount is justified until growth visibility improves.
Sign up to view all
DOCS 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Doximity presents a complex picture: its exceptional fundamental quality (margins, cash flow, balance sheet) is undeniable, but the severe growth deceleration is a major red flag that has rightly crushed the stock. The current valuation appears to price in significant pessimism, offering a margin of safety, but without evidence of growth stabilization, it is difficult to be bullish. The stance would upgrade to bullish on confirmation of sustained revenue growth above 12% and net margin stability above 30%. It would turn bearish if revenue growth falls below 8% or if the stock decisively breaks below the $17.15 support level.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Doximity's 12-month outlook, with a consensus price target around $26.59 and implied upside of +30.0% versus the current price.
Average Target
$26.59
2 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
2
covering this stock
Price Range
$16 - $27
Analyst target range
Analyst coverage appears limited with only 2 analysts providing estimates for future EPS and revenue, suggesting insufficient data for a robust consensus on price targets and recommendations. The implications of limited coverage include higher volatility, less efficient price discovery, and typically lower institutional interest, which is consistent with the stock's recent dramatic price moves and high beta. Without a clear consensus price target or buy/hold/sell distribution from the provided data, the analyst sentiment must be inferred from recent institutional ratings; actions in February and March 2026 show a mix of maintained Overweight/Outperform ratings (RBC Capital, Piper Sandler, Barclays, Morgan Stanley) and Neutral ratings (JP Morgan, Mizuho, Goldman Sachs), with one upgrade from Hold to Buy (Canaccord Genuity). This pattern indicates a cautiously optimistic to neutral stance among covering firms, with the wide target price range implied by differing ratings signaling high uncertainty regarding the company's near-term growth path and appropriate valuation following its guidance reset.
Bulls vs Bears: DOCS Investment Factors
The investment debate for Doximity is a classic clash between a high-quality, profitable business model and a deteriorating near-term growth trajectory. The bull case is anchored in the company's exceptional 89.9% gross margins, robust $311.5M free cash flow, dominant market position, and valuation now trading near historical lows. The bear case is driven by the alarming deceleration of revenue growth to 9.8% YoY, severe stock price decline of -58.8% over the past year, and signs of margin compression. Currently, the bear side has stronger evidence, as the dramatic price action and growth slowdown are immediate, concrete realities that outweigh the company's still-strong fundamentals. The single most important tension is whether Doximity's growth deceleration is a temporary reset or a permanent shift to a lower-growth phase; the resolution of this question will determine if the stock's deep value discount is justified or a major mispricing.
Bullish
- Exceptional Profitability and Cash Flow: Doximity maintains an exceptionally high gross margin of 89.9% and a net margin of 33.3%, demonstrating the efficiency of its asset-light platform model. The company generates substantial free cash flow, with TTM FCF of $311.5 million, providing ample liquidity for operations and strategic investments without relying on debt.
- Dominant Market Position and Strong Balance Sheet: As the dominant digital platform for U.S. medical professionals, Doximity benefits from significant network effects and a critical role in healthcare infrastructure. The company's balance sheet is pristine, with a debt-to-equity ratio of 0.011 and a current ratio of 6.09, indicating minimal financial risk and strong liquidity.
- Valuation at Historical Lows: The stock's trailing P/E of 22.2x is near the lower end of its historical range, a significant de-rating from its former high-growth premium. The forward P/E of 13.4x suggests the market is pricing in depressed earnings, potentially offering a value entry point if growth stabilizes.
- Analyst Sentiment Cautiously Optimistic: Despite the sharp sell-off, recent institutional analyst actions in early 2026 included maintained Overweight/Outperform ratings from several major firms. This suggests professional analysts see underlying value and a potential for recovery, even amidst near-term uncertainty.
Bearish
- Severe Revenue Growth Deceleration: Q3 FY2026 revenue growth decelerated sharply to 9.8% YoY, down from 22.1% in the year-ago quarter. This significant slowdown in the core subscription business (94.8% of revenue) raises serious concerns about market saturation and the company's ability to re-accelerate growth.
- Extreme Technical Downtrend and Underperformance: The stock is in a severe downtrend, down 58.8% over the past year and 58.4% over the past six months, significantly underperforming the SPY's 28.2% gain. The price is just 28% above its 52-week low of $17.15, reflecting persistent negative momentum and a lack of near-term catalysts.
- Profitability Metrics Softening: While still strong, profitability has softened, with Q3 net income of $61.6 million and a net margin of 33.3% down from $75.2 million and a 44.6% margin in the prior-year quarter. This margin compression indicates rising costs or investment needs that could pressure future earnings.
- High Volatility and Limited Analyst Coverage: With a beta of 1.35, DOCS is 35% more volatile than the market, amplifying downside risk. Limited analyst coverage (only 2 providing estimates) contributes to higher volatility and less efficient price discovery, making the stock riskier for investors.
DOCS Technical Analysis
The stock is in a severe and sustained downtrend, evidenced by a 1-year price change of -58.80% and a 6-month decline of -58.40%. As of the latest close at $21.40, the price is trading near the bottom of its 52-week range, approximately 28% above the 52-week low of $17.15 and 72% below the 52-week high of $76.51; this positioning suggests the stock is deeply oversold and may represent a value opportunity, though it also indicates significant fundamental deterioration and negative momentum that could persist. Recent momentum remains negative and aligned with the longer-term downtrend, with the stock down -11.57% over the past month and -12.76% over the past three months; this continued weakness, including a sharp drop from $26.45 to $18.01 between May 12-14, 2026, confirms bearish sentiment and a lack of near-term catalysts for recovery. Key technical support is the 52-week low of $17.15, while resistance lies at the recent pre-earnings level near $26.45; a breakdown below $17.15 would signal a new leg down, while a sustained move above $26 would be needed to suggest a trend reversal. The stock's beta of 1.353 indicates it is approximately 35% more volatile than the broader market (SPY), which has gained 28.21% over the past year, highlighting DOCS's severe underperformance and elevated risk profile for investors.
Beta
1.29
1.29x market volatility
Max Drawdown
-76.0%
Largest decline past year
52-Week Range
$17-$77
Price range past year
Annual Return
-64.8%
Cumulative gain past year
| Period | DOCS Return | S&P 500 |
|---|---|---|
| 1m | -21.3% | -0.1% |
| 3m | -17.0% | +9.0% |
| 6m | -53.7% | +7.0% |
| 1y | -64.8% | +22.9% |
| ytd | -52.8% | +8.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
DOCS Fundamental Analysis
Revenue growth has decelerated significantly, with Q3 FY2026 revenue of $185.1 million representing a year-over-year increase of 9.76%, a sharp slowdown from the 22.1% YoY growth seen in the year-ago quarter (Q3 FY2025 revenue: $168.6 million). The subscription segment, constituting $175.4 million or 94.8% of total revenue, is the primary driver, but the decelerating growth trend raises concerns about market saturation or competitive pressures impacting the core business. The company remains highly profitable with strong margins, reporting Q3 net income of $61.6 million and a net margin of 33.27%, supported by an exceptional gross margin of 89.89%. However, profitability metrics have softened year-over-year, as Q3 FY2025 net income was higher at $75.2 million with a net margin of 44.60%, indicating some margin compression likely due to increased operating expenses or investment needs. The balance sheet is exceptionally strong with minimal debt and robust cash generation, evidenced by a debt-to-equity ratio of only 0.011 and a current ratio of 6.09, indicating ample liquidity. Trailing twelve-month free cash flow is a substantial $311.5 million, and Return on Equity (ROE) is a healthy 20.62%, demonstrating the company's ability to generate significant cash from its asset-light model and fund operations internally without reliance on external financing.
Quarterly Revenue
$185053000.0B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.89%
Latest Quarter
Free Cash Flow
$311547000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is DOCS Overvalued?
Given a positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 22.23x, while the forward PE is significantly lower at 13.42x, implying the market expects a substantial recovery in earnings growth or is pricing in currently depressed earnings. The gap suggests the market anticipates improved profitability or is applying a discount due to growth concerns. Compared to sector averages, Doximity's trailing PE of 22.23x and Price-to-Sales (PS) ratio of 6.76x are not directly comparable without a provided industry average, but the high gross margin of 89.1% and net margin of 30.4% typically command premium multiples; the current discount relative to its own historical highs may reflect justified concerns over growth deceleration. Historically, the stock's current trailing PE of 22.23x is near the lower end of its observable range over recent years, which has seen ratios frequently above 30x and even above 50x; trading near historical lows suggests the market is pricing in pessimistic expectations, potentially offering a value entry point if the company can stabilize its growth trajectory, but it also reflects a significant de-rating from its former high-growth premium.
PE
22.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 27x~112x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
19.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks center on the sharp deceleration in revenue growth, which fell to 9.8% YoY in Q3 FY2026 from 22.1% a year prior. This raises the risk of market saturation for its core subscription product, which constitutes 94.8% of total revenue. While the company is highly profitable, net margin compression from 44.6% to 33.3% year-over-year indicates rising operating expenses that could further pressure earnings if growth does not re-accelerate to justify them.
Market & Competitive Risks are elevated due to the stock's high beta of 1.353, making it 35% more volatile than the market and highly sensitive to broader risk-off sentiment. The stock has already undergone severe valuation compression, trading at a forward P/E of 13.4x, but remains at risk of further de-rating if growth continues to disappoint. Competitive or regulatory disruption to its physician network moat, though not currently evident, represents an existential threat given its revenue concentration.
The Worst-Case Scenario involves Doximity failing to stabilize its growth, with revenue growth decelerating further into the low-to-mid single digits. This could trigger another wave of analyst downgrades and institutional selling, breaking key technical support at the 52-week low of $17.15. A realistic downside from the current price of $21.40 would be a decline of approximately -20% to retest that low, with potential for an overshoot towards the $15 range if sentiment turns decisively negative, representing a loss of up to -30%.
FAQ
The key risks are, in order of severity: 1) Growth Deceleration Risk: Revenue growth slowed sharply to 9.8% YoY, raising saturation concerns. 2) Market Sentiment & Volatility Risk: With a beta of 1.35, the stock is 35% more volatile than the market, amplifying losses in downturns. 3) Profitability Compression Risk: Net margin fell from 44.6% to 33.3% YoY; further erosion would hurt earnings. 4) Limited Coverage Risk: Only 2 analysts provide estimates, leading to less price stability and higher uncertainty for investors.
The 12-month forecast is highly bifurcated, with a base case target range of $22-$28 (55% probability), a bull case of $32-$40 (25%), and a bear case of $15-$19 (20%). The most likely scenario (base case) assumes revenue growth stabilizes in the high-single to low-double digits, with the stock trading in a range based on its value and cash flow characteristics. The key assumption behind this forecast is that the company's growth does not decelerate further but also fails to re-accelerate meaningfully, leaving the stock in a valuation limbo.
DOCS appears fairly valued to slightly undervalued relative to its own fundamentals but the discount is justified by growth concerns. Its trailing P/E of 22.2x and forward P/E of 13.4x are near historical lows, a significant de-rating from when it traded as a high-growth stock. Compared to its exceptional profitability (30.4% net margin) and asset-light model, these multiples suggest the market is paying a fair or discounted price. However, the valuation implies the market expects sustained slower growth, making it fairly valued until the company proves it can re-accelerate.
DOCS is a speculative buy, not a clear-cut good buy, suitable only for investors with a high risk tolerance and a long-term horizon. The stock offers a compelling value proposition, trading at a forward P/E of 13.4x with exceptional 89.9% gross margins, but this is counterbalanced by severe risks, most notably a sharp revenue growth deceleration to 9.8% YoY. It could be a good buy for value-oriented investors betting on a growth stabilization, but it is a poor choice for those seeking stability or near-term catalysts, given its -58.8% one-year decline and high volatility.
DOCS is unsuitable for short-term trading due to its high volatility (beta 1.35) and lack of near-term positive catalysts. It is only appropriate for long-term investors with a minimum horizon of 2-3 years who believe in the company's underlying network moat and are willing to wait for a potential growth turnaround. The stock does not pay a dividend, so returns are solely dependent on price appreciation, which requires time for the fundamental story to improve. Given the current uncertainty, it is a speculative long-term holding, not a trade.